Veeva Systems delivered a strong close to fiscal 2026 with Q4 revenue of $835.95 million and full-year revenue of $3.195 billion, underscoring the company’s ability to execute across its diversified life-sciences cloud platform. Non-GAAP operating income for the quarter was $366 million and $1.434 billion for the year, reflecting a robust margin profile and ongoing operating leverage as the company scales. Management underscored AI as a driver of automation rather than a single catalyst, emphasizing the enduring value of core systems, data quality, and workflow integrity in regulated pharma environments. In the near term, Vault CRM adoption continued to gain traction (roughly 140 live Vault CRM customers, with ongoing migrations of top-20 accounts), while RTSM leadership and EDC-related growth remain central to the roadmap. Crossix again contributed meaningfully to outperformance, though management cautioned that 2027 will feature tougher comparisons as the prior year’s gains lap.
Looking ahead, Veeva guided to a 13% revenue growth trajectory for FY2027 (annual normalized billings to be updated quarterly; no quarterly billings guidance), with seasonality expected to mirror the prior year. The company continues to pursue strategic opportunities in AI-enabled automation, CRO channel expansion, and deeper CRM add-ons (e.g., Campaign Manager, Service Center, Network/OpenData). Management highlighted a long-term ambition to have CRM represent roughly 10% of revenue by 2030, reinforcing a path to durable, scalable growth. Investors should monitor AI solution adoption velocity, RTSM/EDC execution and integration, Vault CRM migrations, and the cadence of Crossix and CRM-related wins as primary drivers of the next phase of growth.